Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins

San Chiang Wu, Jeng Chuan Shiang, Shoa Lin Lin, Te Lang Wu, Wei Chun Huang, Kuan Rau Chiou, Chun Peng Liu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Information of the effect of statin on lipoproteins such as apolipoprotein (apo) A-I, lipoprotein (a) [Lp (a)], or apolipoprotein B levels is limited. This investigation was a crossover study designed to evaluate the efficacy and safety of atorvastatin and simvastatin in patients with hyperlipidemia. Sixty-six patients were involved in the study. Group I consisted of 32 patients, who were first treated with atorvastatin (10mg) then switched to simvastatin (10mg). Group II consisted of 34 patients, who were first treated with simvastatin then switched to atorvastatin. Each regimen was used for 3 months (phase I), stopped for 2 months, and then restarted for another 3 months (phase II). Both statins effectively reduced total cholesterol, low-density lipoprotein cholesterol (LDL-C), apo B, and Lp (a) (P < 0.001 in all comparisons). A significant increase in the high-density lipoprotein cholesterol (HDL-C) was noted after both statin treatments (P < 0.05 in all comparisons). Both statins caused an increase in the apo A-I levels, and the extent of changes in apo A-I revealed no difference between the two drugs. Compared to the simvastatin group, there were more patients in the atorvastatin group achieving the National Cholesterol Education Program ATP-III LDL-C goal (P < 0.05) and European LDL-C goal (P < 0.001). Both treatments were well tolerated; no patient was withdrawn from the study. This study demonstrates that both statins can effectively improve lipid profiles in patients with hyperlipidemia. Atorvastatin is more effective in helping patients reach the ATP-III and European LDL-C goals than simvastatin at the same dosage.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalHeart and Vessels
Volume20
Issue number5
DOIs
Publication statusPublished - Sep 1 2005
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Lipoproteins
Simvastatin
Safety
Apolipoprotein A-I
LDL Cholesterol
Lipoprotein(a)
Apolipoproteins B
Hyperlipidemias
Adenosine Triphosphate
Cholesterol
Cross-Over Studies
HDL Cholesterol
Atorvastatin Calcium
Lipids
Education
Therapeutics

Keywords

  • Cholesterol
  • Hyperlipidemia
  • Lipoprotein
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wu, S. C., Shiang, J. C., Lin, S. L., Wu, T. L., Huang, W. C., Chiou, K. R., & Liu, C. P. (2005). Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. Heart and Vessels, 20(5), 217-223. https://doi.org/10.1007/s00380-005-0836-6

Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. / Wu, San Chiang; Shiang, Jeng Chuan; Lin, Shoa Lin; Wu, Te Lang; Huang, Wei Chun; Chiou, Kuan Rau; Liu, Chun Peng.

In: Heart and Vessels, Vol. 20, No. 5, 01.09.2005, p. 217-223.

Research output: Contribution to journalArticle

Wu, San Chiang ; Shiang, Jeng Chuan ; Lin, Shoa Lin ; Wu, Te Lang ; Huang, Wei Chun ; Chiou, Kuan Rau ; Liu, Chun Peng. / Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. In: Heart and Vessels. 2005 ; Vol. 20, No. 5. pp. 217-223.
@article{e9fcf5be9ad24e129c73e333bc8c7742,
title = "Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins",
abstract = "Information of the effect of statin on lipoproteins such as apolipoprotein (apo) A-I, lipoprotein (a) [Lp (a)], or apolipoprotein B levels is limited. This investigation was a crossover study designed to evaluate the efficacy and safety of atorvastatin and simvastatin in patients with hyperlipidemia. Sixty-six patients were involved in the study. Group I consisted of 32 patients, who were first treated with atorvastatin (10mg) then switched to simvastatin (10mg). Group II consisted of 34 patients, who were first treated with simvastatin then switched to atorvastatin. Each regimen was used for 3 months (phase I), stopped for 2 months, and then restarted for another 3 months (phase II). Both statins effectively reduced total cholesterol, low-density lipoprotein cholesterol (LDL-C), apo B, and Lp (a) (P < 0.001 in all comparisons). A significant increase in the high-density lipoprotein cholesterol (HDL-C) was noted after both statin treatments (P < 0.05 in all comparisons). Both statins caused an increase in the apo A-I levels, and the extent of changes in apo A-I revealed no difference between the two drugs. Compared to the simvastatin group, there were more patients in the atorvastatin group achieving the National Cholesterol Education Program ATP-III LDL-C goal (P < 0.05) and European LDL-C goal (P < 0.001). Both treatments were well tolerated; no patient was withdrawn from the study. This study demonstrates that both statins can effectively improve lipid profiles in patients with hyperlipidemia. Atorvastatin is more effective in helping patients reach the ATP-III and European LDL-C goals than simvastatin at the same dosage.",
keywords = "Cholesterol, Hyperlipidemia, Lipoprotein, Statin",
author = "Wu, {San Chiang} and Shiang, {Jeng Chuan} and Lin, {Shoa Lin} and Wu, {Te Lang} and Huang, {Wei Chun} and Chiou, {Kuan Rau} and Liu, {Chun Peng}",
year = "2005",
month = "9",
day = "1",
doi = "10.1007/s00380-005-0836-6",
language = "English",
volume = "20",
pages = "217--223",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins

AU - Wu, San Chiang

AU - Shiang, Jeng Chuan

AU - Lin, Shoa Lin

AU - Wu, Te Lang

AU - Huang, Wei Chun

AU - Chiou, Kuan Rau

AU - Liu, Chun Peng

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Information of the effect of statin on lipoproteins such as apolipoprotein (apo) A-I, lipoprotein (a) [Lp (a)], or apolipoprotein B levels is limited. This investigation was a crossover study designed to evaluate the efficacy and safety of atorvastatin and simvastatin in patients with hyperlipidemia. Sixty-six patients were involved in the study. Group I consisted of 32 patients, who were first treated with atorvastatin (10mg) then switched to simvastatin (10mg). Group II consisted of 34 patients, who were first treated with simvastatin then switched to atorvastatin. Each regimen was used for 3 months (phase I), stopped for 2 months, and then restarted for another 3 months (phase II). Both statins effectively reduced total cholesterol, low-density lipoprotein cholesterol (LDL-C), apo B, and Lp (a) (P < 0.001 in all comparisons). A significant increase in the high-density lipoprotein cholesterol (HDL-C) was noted after both statin treatments (P < 0.05 in all comparisons). Both statins caused an increase in the apo A-I levels, and the extent of changes in apo A-I revealed no difference between the two drugs. Compared to the simvastatin group, there were more patients in the atorvastatin group achieving the National Cholesterol Education Program ATP-III LDL-C goal (P < 0.05) and European LDL-C goal (P < 0.001). Both treatments were well tolerated; no patient was withdrawn from the study. This study demonstrates that both statins can effectively improve lipid profiles in patients with hyperlipidemia. Atorvastatin is more effective in helping patients reach the ATP-III and European LDL-C goals than simvastatin at the same dosage.

AB - Information of the effect of statin on lipoproteins such as apolipoprotein (apo) A-I, lipoprotein (a) [Lp (a)], or apolipoprotein B levels is limited. This investigation was a crossover study designed to evaluate the efficacy and safety of atorvastatin and simvastatin in patients with hyperlipidemia. Sixty-six patients were involved in the study. Group I consisted of 32 patients, who were first treated with atorvastatin (10mg) then switched to simvastatin (10mg). Group II consisted of 34 patients, who were first treated with simvastatin then switched to atorvastatin. Each regimen was used for 3 months (phase I), stopped for 2 months, and then restarted for another 3 months (phase II). Both statins effectively reduced total cholesterol, low-density lipoprotein cholesterol (LDL-C), apo B, and Lp (a) (P < 0.001 in all comparisons). A significant increase in the high-density lipoprotein cholesterol (HDL-C) was noted after both statin treatments (P < 0.05 in all comparisons). Both statins caused an increase in the apo A-I levels, and the extent of changes in apo A-I revealed no difference between the two drugs. Compared to the simvastatin group, there were more patients in the atorvastatin group achieving the National Cholesterol Education Program ATP-III LDL-C goal (P < 0.05) and European LDL-C goal (P < 0.001). Both treatments were well tolerated; no patient was withdrawn from the study. This study demonstrates that both statins can effectively improve lipid profiles in patients with hyperlipidemia. Atorvastatin is more effective in helping patients reach the ATP-III and European LDL-C goals than simvastatin at the same dosage.

KW - Cholesterol

KW - Hyperlipidemia

KW - Lipoprotein

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=25844452641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844452641&partnerID=8YFLogxK

U2 - 10.1007/s00380-005-0836-6

DO - 10.1007/s00380-005-0836-6

M3 - Article

C2 - 16160904

AN - SCOPUS:25844452641

VL - 20

SP - 217

EP - 223

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 5

ER -